77 search results for: symposium

Charting the Future: Preventing the Atopic March
Dermatology
Charting the Future: Preventing the Atopic March
expert video

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga discusses data identifying atopic dermatitis as the first diagnosed atopic disease and the start of the atopic march.

View more
Charting the Future: Preventing the Atopic March
Dermatology
Charting the Future: Preventing the Atopic March
expert video

In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga highlights the multidimensional burden of uncontrolled AD and how the various burdens contribute to Cumulative Life Course Impairment (CLCI).

View more
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
Rhinology
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
expert video

The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.

View more
Head-to-Head Trials of Biologics in CRSwNP
Rhinology
Head-to-Head Trials of Biologics in CRSwNP
expert video

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.

View more
Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP
Rhinology
Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP
expert video

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.

View more
ADVENT at EADV 2026
On Demand
Stepping Up: Expert Perspectives on CSU From Diagnosis to Disease Control

Drs Martin Metz, Moshe Ben-Shoshan, and Michelle Tarbox shared expert perspectives on chronic spontaneous urticaria (CSU) during an engaging ADVENT symposium at EADV 2026 in Vienna, Austria. The symposium explored key considerations across the CSU patient journey, from diagnosis to disease control. Key topics included the multifaceted burden of CSU on patients, caregivers, and families, practical approaches to diagnosis and assessment of disease control, and considerations for treatment escalation and advanced therapy selection in adult and pediatric patients with CSU.

ADVENT at EADV 2026
On Demand
Atopic Dermatitis at ​an Inflection Point: ​Refining Outcomes Through Timely, Targeted Intervention

Prof. Tilo Biedermann and Drs. Nicole Chase and Lisa Swanson presented an engaging ADVENT educational symposium at EADV 2026 on September 30 in Vienna, Austria, focusing on the local and systemic role of type 2 inflammation in atopic dermatitis (AD) and its implications for disease management across the lifespan. The symposium explored the potential to achieve sustained optimal disease control with systemic therapy in adults, as well as the potential window of opportunity for early intervention to reduce or prevent multidimensional disease burden in pediatric AD.

ADVENT at WCI
Congress
12
October
2025
Congress
ADVENT at WCI 2025

Join ADVENT for an educational symposium on PN at WCI 2025!

ADVENT at WCI
On Demand
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice

Join Professors Matthias Augustin and Sarina Elmariah for an engaging ADVENT symposium as they explore the pivotal role of type 2 inflammation in prurigo nodularis and chronic itch.

Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
Dermatology
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
expert video

This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.

View more
.
Congress
9
March
2024
Congress
The Benefits of Early Intervention in AD: More Than Skin Deep

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

ADVENT at NAPNAP 2025
Congress
12
March
2025
Congress
ADVENT at NAPNAP 2025

Join experts Jonathan Spergel, MD, PhD, Wanda Phipatanakul, MD, MS, and Jerry Ellen Schonfeld, CPNP, at an educational symposium as they investigate the role of type 2 inflammation in pediatric diseases. The speakers will also discuss the difficulties in diagnosis and burdens patients and their families face.